Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage
16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, who are impacted by the tocilizumab stock shortage.
“In New Zealand, about 400 people currently use PHARMAC funded tocilizumab for a number of conditions such as rheumatoid and juvenile idiopathic arthritis,” explains PHARMAC’s director of operations Lisa Williams.
